Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough
Abstract
Fibrosis-Associated CoughThis study evaluated whether oral nalbuphine extended release (ER) reduces cough and improves patient-reported outcomes in patients with idiopathic pulmonary fibrosis (IPF) and chronic cough. Why Does This Clinical Trial Matter?IPF is a progressive lung disease with high rates of mortality and significant impairment in quality of life.Up to 80% of patients with IPF experience chronic cough and current treatments do not effectively address this symptom.New options are needed. Nalbuphine ER 27 mg 42 patientsNalbuphine ER 54 mg 43 patients Nalbuphine ER 108 mg 40 patients Placebo 40 patients
Fields of Study & Subjects
Respiratory and Cough-Related Research
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Chronic Obstructive Pulmonary Disease (COPD) Research
Publication details
- Journal / source
- JAMA
- Publisher
- American Medical Association (AMA)
- Volume
- 335
- Issue
- 12
- Pages
- e2526285–e2526285
- Publication date
- 22 January 2026
- Language
- EN